Thursday - April 21, 2022

Bayer appoints Tara Frenkl as the new Head of Oncology Development at its Oncology Strategic Business Unit

download
Tara Frenkl

Berlin, April 21, 2022 – Bayer today announced Tara Frenkl, MD, MPH as the new Head of Oncology Development at its Oncology Strategic Business Unit, effective April 25, 2022. She will report to Christine Roth, Head of the Oncology Strategic Business Unit at the company’s Pharmaceuticals Division. Prior to joining Bayer, she held the role of Senior Vice President, Head of Medicine Development Leaders in Oncology at GlaxoSmithKline, with strategic impact on the global development of medicines across the company’s Oncology portfolio.

“We are pleased to welcome Tara as the new Head of Oncology Development. Her broad experience, passion and dedication go hand in hand with Bayer`s commitment to put patients at the center of it all. It is important that we stay focused on the science coupled with speed and innovation to help bring new medications and indications as quickly as possible,” said Christine Roth. “Tara`s leadership style is characterized by expertise and innovative thinking. She brings experience from all aspects of research and development, including clinical development, regulatory and global development strategy.”

Prior to joining GlaxoSmithKline, Tara Frenkl was at Merck & Co., Inc. for 13 years in roles of increasing responsibility.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.


Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma


Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Download Center
0
file(s) collected

View Download Center

Contact


Astrid Kranz

Head of Communication Key Therapeutic Areas
Phone +49 30 2215-41596